{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:08:16Z","timestamp":1794866896775,"version":"4.9.1"},"reference-count":71,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.1001\/jamaophthalmol.2021.0640","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T04:31:11Z","timestamp":1618633871000},"page":"610","source":"Crossref","is-referenced-by-count":55,"title":["Cardiovascular Adverse Events With Intravitreal Anti\u2013Vascular Endothelial Growth Factor Drugs"],"prefix":"10.1001","volume":"139","author":[{"given":"Nad\u00e8ge","family":"Ngo Ntjam","sequence":"first","affiliation":[{"name":"Hospital Pharmacy, CHRU de Tours, Tours, France"},{"name":"EA 4245, T2I (Transplantation, Immunity & Inflammation), Universit\u00e9 de Tours, Tours, France"},{"name":"Medical Pharmacology Department, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Thulliez","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, CHU de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[{"name":"EA 4245, T2I (Transplantation, Immunity & Inflammation), Universit\u00e9 de Tours, Tours, France"},{"name":"Medical Pharmacology Department, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Salvo","sequence":"additional","affiliation":[{"name":"Medical Pharmacology Department, CHU Pellegrin, Bordeaux, France"},{"name":"Bordeaux Population Health Research Center, U1219, Universit\u00e9 de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[{"name":"EA 4245, T2I (Transplantation, Immunity & Inflammation), Universit\u00e9 de Tours, Tours, France"},{"name":"Cardiology Department, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Pisella","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[{"name":"EA 4245, T2I (Transplantation, Immunity & Inflammation), Universit\u00e9 de Tours, Tours, France"},{"name":"Medical Pharmacology Department, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"eoi210016r1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010.","volume":"96","author":"Pascolini","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"eoi210016r2","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990-2010: a systematic analysis.","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob Health"},{"issue":"6","key":"eoi210016r3","first-page":"638","article-title":"Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.","volume":"72","author":"Pe\u2019er","year":"1995","journal-title":"Lab Invest"},{"issue":"6","key":"eoi210016r4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi210016r5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial.","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi210016r6","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2008.08.012","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.","volume":"115","author":"Ip","year":"2008","journal-title":"Ophthalmology"},{"issue":"19","key":"eoi210016r7","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"eoi210016r8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"eoi210016r9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bcp.12758","article-title":"Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.","volume":"81","author":"Zhang","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"eoi210016r10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients.","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"eoi210016r11","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitrealaflibercept, bevacizumab, and ranibizumab.","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"9","key":"eoi210016r12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/IAE.0000000000002004","article-title":"Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema.","volume":"38","author":"Hirano","year":"2018","journal-title":"Retina"},{"key":"eoi210016r13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12886-015-0035-x","article-title":"Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME).","volume":"15","author":"Korobelnik","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"eoi210016r14","article-title":"Aflibercept for neovascular age-related macular degeneration.","volume":"2","author":"Sarwar","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"eoi210016r15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-015-0017-z","article-title":"Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment.","volume":"15","author":"Song","year":"2015","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"eoi210016r16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaophthalmol.2018.0002","article-title":"Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti-vascular endothelial growth factor medication use.","volume":"136","author":"Thulliez","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"eoi210016r17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.","volume":"132","author":"Thulliez","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"eoi210016r18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"eoi210016r19","doi-asserted-by":"publisher","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA Harms checklist: improving harms reporting in systematic reviews.","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"eoi210016r20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"6921","key":"eoi210016r21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration.","volume":"308","year":"1994","journal-title":"BMJ"},{"issue":"6","key":"eoi210016r22","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study.","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi210016r23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"14","key":"eoi210016r24","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"eoi210016r25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi210016r26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00417-016-3472-1","article-title":"A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.","volume":"255","author":"Callanan","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"eoi210016r27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/1120672117750058","article-title":"A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.","volume":"28","author":"Bandello","year":"2018","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"eoi210016r28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi210016r29","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi210016r30","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ajo.2007.12.029","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.","volume":"145","author":"Antoszyk","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"eoi210016r31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jfo.2015.03.016","article-title":"[Comparison of early management of central retinal vein occlusion with ranibizumab versus hemodilution].","volume":"38","author":"Graber","year":"2015","journal-title":"J Fr Ophtalmol"},{"issue":"14","key":"eoi210016r32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"eoi210016r33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi210016r34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study).","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi210016r35","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/aos.12488","article-title":"Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.","volume":"93","author":"Pielen","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"eoi210016r36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","article-title":"Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.","volume":"257","author":"Li","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"eoi210016r37","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1111\/aos.13574","article-title":"The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.","volume":"96","author":"Lang","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"eoi210016r38","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"eoi210016r39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jcjo.2014.12.014","article-title":"Efficacy\/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.","volume":"50","author":"Berger","year":"2015","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"eoi210016r40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi210016r41","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL Study.","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi210016r42","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi210016r43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ajo.2013.08.013","article-title":"Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.","volume":"157","author":"Tan","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"eoi210016r45","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi210016r46","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"10085","key":"eoi210016r47","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"eoi210016r48","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi210016r49","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.ophtha.2011.02.018","article-title":"The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.","volume":"118","author":"Do","year":"2011","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi210016r50","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi210016r51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.oret.2019.08.001","article-title":"Efficacy and safety of ranibizumab in Asian patients with branch retinal vein occlusion: results from the randomized BLOSSOM Study.","volume":"4","author":"Wei","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"eoi210016r52","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1111\/aos.13381","article-title":"Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).","volume":"96","author":"Hattenbach","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"eoi210016r53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","article-title":"Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.","volume":"169","author":"Hoerauf","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"eoi210016r54","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"eoi210016r55","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ajo.2014.02.019","article-title":"A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).","volume":"157","author":"Comyn","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"eoi210016r56","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi210016r57","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi210016r58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10792-016-0241-4","article-title":"Safety and complications of intravitreal injections performed in an Asian population in Singapore.","volume":"37","author":"Xu","year":"2017","journal-title":"Int Ophthalmol"},{"issue":"9","key":"eoi210016r59","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40261-018-0678-5","article-title":"Real-world safety of intravitreal bevacizumab and ranibizumab treatments for retinal diseases in Thailand: a prospective observational study.","volume":"38","author":"Sangroongruangsri","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"4","key":"eoi210016r60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00417-018-3917-9","article-title":"Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.","volume":"256","author":"Hanhart","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"eoi210016r61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaophthalmol.2019.4636","article-title":"Risk of death associated with intravitreal anti\u2013vascular endothelial growth factor therapy: a systematic review and meta-analysis.","volume":"138","author":"Reibaldi","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"eoi210016r62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard.","volume":"7","author":"Schmucker","year":"2012","journal-title":"PLoS One"},{"issue":"13","key":"eoi210016r63","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1167\/iovs.17-22431","article-title":"Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model.","volume":"58","author":"Christoforidis","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"eoi210016r64","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.oret.2016.12.015","article-title":"Serious adverse events with bevacizumab or ranibizumab for age-related macular degeneration: meta-analysis of individual patient data.","volume":"1","author":"Maguire","year":"2017","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"eoi210016r65","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice.","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi210016r66","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022031","article-title":"Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.","volume":"9","author":"Pham","year":"2019","journal-title":"BMJ Open"},{"issue":"9","key":"eoi210016r67","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi210016r68","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi210016r69","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.oret.2018.04.018","article-title":"Systemic safety in ranibizumab-treated patients with neovascular age-related macular degeneration: a patient-level pooled analysis.","volume":"2","author":"Zarbin","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"eoi210016r70","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamaophthalmol.2017.0455","article-title":"Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials.","volume":"135","author":"Zarbin","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi210016r71","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ophtha.2004.10.039","article-title":"Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies.","volume":"112","author":"Wong","year":"2005","journal-title":"Ophthalmology"},{"key":"eoi210016r44","author":"Tufail","year":"2010"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2778626\/jamaophthalmology_ngo_ntjam_2021_oi_210016_1623191627.57199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T15:02:13Z","timestamp":1623855733000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2778626"}},"subtitle":["A Systematic Review and Meta-analysis of Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.0640","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}